JOINN Laboratories (China) Co., Ltd. (stock code: 603127.SH/6127.HK) was successfully listed on the main board of the Hong Kong Stock Exchange on February 26, 2021, which is also the Chinese Lantern Festival of the Year of the Ox. The company's H-shares were issued at a price of HK $151 per share, with a total of about 43.32 million shares issued and a net raised amount of about HK $6.286 billion (assuming the overallotment right is not exercised). The funds raised by the company's H-share issuance will be mainly used to build and expand non-clinical service facilities, improve the scale and technical capacity of non-clinical service facilities both at home and abroad, improve the global business layout and enhance the global service capacity; Upgrading and expanding laboratory animal and disease model development facilities to support our non-clinical research operations; Increase investment in clinical trial operations to improve our comprehensive service capabilities; The company will also seek appropriate strategic acquisitions to extend the service chain and accelerate business growth; Part of the money will be used to supplement working capital.

From the successful listing on the main board of the Shanghai Stock Exchange in August 2017 to the successful listing on the main board of the Hong Kong Stock Exchange today, the company has opened a new chapter in the capital market of A+H. The company will make full use of the platform of Hong Kong stock capital market, with the support of overseas investors, deepen the overseas business layout, improve the global pharmaceutical research and development service capacity, and boost the new drug research and development of global customers.

Ms. Yuxia Feng, Chairman and Founder of the Company, said, "The Hong Kong listing is another important milestone for JOINN’s efforts to further expand the international market, facilitate global drug innovation, accelerate the development of new drugs and reduce human suffering."